Kamada Q3 net income jumps 51% to $7.99 million
KMDA•Kamada’s third-quarter 2026 net income rose 51% year over year to $7.99 million, while revenue increased 11% to $52.03 million. The company raised its 2026 revenue guidance to $205 million–$208 million and projected double-digit revenue growth in 2027.
1. Quarterly results and outlook
Kamada reported third-quarter 2026 revenue of $52.03 million, up 11% year over year, primarily driven by increased KEDRAB, VARIZIG and HEPAGAM sales. Operating cash flow more than doubled to $37.64 million in the first nine months of 2026. Plasma collection continued ramping up at Texas facilities to support a three-year supply agreement worth approximately $50 million. The company raised its full-year 2026 revenue guidance to $205 million–$208 million and projected double-digit revenue growth in 2027.
